» Articles » PMID: 36115921

Effects of Tumor-infiltrating CD8+ T Cells, PD1/PD-L1 Axis, and Expression Patterns of HLA Class I on the Prognosis of Patients with Malignant Pleural Mesothelioma Who Underwent Extra-pleural Pneumonectomy

Abstract

Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor immunity; however, the clinical impact of these parameters in resected malignant pleural mesothelioma (MPM) cases is unknown. We immunohistochemically evaluated the tumor infiltrated lymphocytes (TILs), PD1/PD-L1 axis, and expression of HLA class I in resected specimens from 58 patients with MPM who underwent extra-pleural pneumonectomy (EPP). Higher infiltration of CD3-TIL, CD8-TIL, and PD1-TIL, loss of HLA class I, and overexpression of PD-L1 by tumor cells (PD-L1 TC) or immune cells (PD-L1 IC) were observed in 34 (58.6%), 27 (46.6%), 41 (70.7%), 45 (77.6%), 29 (50.0%), and 33 (56.4%) of 58 cases, respectively. Interestingly, the CD3-TIL score positively correlated with PD-L1 TC and PD1-TIL scores. HLA class I expression level was inversely correlated with the expression levels of PD-L1 TC and PD-L1 IC. Multivariate analysis showed that age, histology, and node metastasis were independent prognostic factors for 5-year overall survival (OS) and loss of HLA class I coincided with a positive prognosis (p = 0.011). The concomitant lack of infiltrating CD8+ T cells with no loss of HLA class I predicted worse 5-year OS (p = 0.007). Moreover, cluster classifications among multiple immunoparameters showed that categories among CD3/PD-L1 TC/HLA class I (p = 0.043), CD8/PD1/HLA class I (p = 0.032), CD8/PD-L1 TC/HLA class I (p = 0.011), and PD1/PD-L1 TC/HLA class I (p = 0.032) predicted 5-year OS in EPP cases for MPM. These immunoparameters could guide surgical indications for patients with MPM.

Citing Articles

Characterizing soluble immune checkpoint molecules and TGF-β in pleural effusion of malignant pleural mesothelioma.

Okita R, Senoo T, Mimura-Kimura Y, Mimura Y, Murakami T, Ikeda E Sci Rep. 2024; 14(1):15947.

PMID: 38987362 PMC: 11236966. DOI: 10.1038/s41598-024-66189-5.


Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis.

Okita R, Kawamoto N, Okada M, Inokawa H, Yamamoto N, Murakami T Sci Rep. 2023; 13(1):5263.

PMID: 37002247 PMC: 10066199. DOI: 10.1038/s41598-023-31448-4.


Editorial: Complexity of tumor microenvironment: A major culprit in cancer development.

Bukhari I, Zhang Y, Thorne R, Mi Y Front Endocrinol (Lausanne). 2022; 13:1059885.

PMID: 36339412 PMC: 9632616. DOI: 10.3389/fendo.2022.1059885.

References
1.
DeLong P, Carroll R, Henry A, Tanaka T, Ahmad S, Leibowitz M . Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005; 4(3):342-6. DOI: 10.4161/cbt.4.3.1644. View

2.
Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-34. PMC: 2193311. DOI: 10.1084/jem.192.7.1027. View

3.
Treasure T, Lang-Lazdunski L, Waller D, Bliss J, Tan C, Entwisle J . Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011; 12(8):763-72. PMC: 3148430. DOI: 10.1016/S1470-2045(11)70149-8. View

4.
Okita R, Shimizu K, Nojima Y, Saisho S, Nakata M . Tofacitinib overcomes an IFNγ-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad. Thorac Cancer. 2021; 12(6):775-782. PMC: 7952785. DOI: 10.1111/1759-7714.13847. View

5.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View